Evidence map›Paper›PMID 36540145›Full record

ArticleNeurology. Clinical practice2022

Health Care Utilization in the Last Year of Life in Parkinson Disease and Other Neurodegenerative Movement Disorders.

Erica D McKenzie, Veronica A Bruno, Andrew Fong, Pin Cai, Madalene Earp, Richard M Camicioli, Ingrid de Kock, Daniela Buttenschoen, Aynharan Sinnarajah, Janis Miyasaki

Open access · greenAbstract read
In one paragraph

Article in Neurology. Clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. End-of-Life Healthcare Utilization in Lewy Body Dementia.Journal of Alzheimer's disease : JAD · 2024
    Article
  13. Article
  14. Neurologists and Palliative Care: Are We Doing Enough?Neurology. Clinical practice · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Erica D McKenzieDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Veronica A BrunoDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Andrew FongDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Pin CaiDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Madalene EarpDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Richard M CamicioliDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Ingrid de KockDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Daniela ButtenschoenDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Aynharan SinnarajahDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.ORCID https://orcid.org/0000-0002-7967-159X
Janis MiyasakiDepartment of Clinical Neurosciences (EDM, VAB), Cumming School of Medicine, University of Calgary, AB, Canada; Data & Analytics (AF), Alberta Health Services, Calgary, Canada; Clinical Workforce Planning (PC, ME), Alberta Health Services, Calgary, Canada; Division of Neurology (RMC, JM), Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; Department of Oncology (IK, DB), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada; and Department of Medicine (AS), School of Medicine, Queen's University, Kingston, Ontario Canada.
Alberta Health Services · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Neurodegenerative movement disorders are rising in prevalence and are associated with high health care utilization. Generally, health care resources are disproportionately expended in the last year of life. Health care utilization by those with neurodegenerative movement disorders in the last year of life is not well-understood. The goal of this study was to assess the utilization of acute care in the last year of life among individuals with neurodegenerative movement disorders and determine whether outpatient neurology or palliative care affected acute care utilization and place of death. Methods: We conducted a retrospective cross-sectional study including health system administrative data in Alberta, Canada, from 2011 to 2017. Administrative data were used to determine place of death and quantify emergency department (ED) visits, hospitalizations, intensive care unit admissions, and outpatient generalist and specialist visits. Diagnoses were classified by 10th revision of the International Classification of Diseases codes. Stata 16v was used for statistical analyses. Results: Among 1439 individuals (60% male), Parkinson disease (n = 1226), progressive supranuclear palsy (n = 78), multiple system atrophy (n = 47), and Huntington disease (n = 58) were the most common diagnoses. The most frequent place of death was in hospital (45.9%), followed by long-term care (36.3%), home (7.9%), and residential hospice (4.0%). Most (64.2%) had >1 ED visit, and 14.4% had >3 emergency department visits. Fifty-five percent had >1 hospitalization, and 23.3% spent >30 days in hospital. Few (2.6%) were admitted to ICU. Only 37.2% and 8.8% accessed outpatient neurologist and specialist palliative care services, respectively. Multivariate logistic regression found the odds of dying at home was higher for those who received outpatient palliative consultation (OR, 2.49, 95% confidence interval [CI], 1.48-4.21, Discussion: There are high rates of in-hospital death and acute care utilization in the year before death among those with neurodegenerative movement disorders. Most did not access specialist palliative or neurologic care in the last year of life. Outpatient palliative care and home care services were associated with increased odds of dying at home. Our results indicate the need for further research into the causes, costs, and potential modifiers to inform public health planning.

Identifiers

PMID36540145
PMCPMC9757116
OpenAlexW4304807893

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.